35.10 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||29.00 x 900|
|Ask||50.00 x 1400|
|Day's Range||33.34 - 35.15|
|52 Week Range||28.54 - 69.81|
|Beta (3Y Monthly)||1.25|
|PE Ratio (TTM)||27.55|
|Earnings Date||Feb 19, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.25|
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase HYALOFAST, a biodegradable, HA-based cartilage repair scaffold, at the 2019 International Cartilage Repair Society Summit.
According to the GuruFocus All-in-One Screener, the following stocks are trading at a discount and have positive three- to five-year future earnings estimates. Warning! GuruFocus has detected 3 Warning Signs with VIA. The discounted cash flow calculator gives the stock a fair value of $52.04 per share, suggesting it has a 44% margin of safety.
Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth quarter. One of these stocks was Anika Therapeutics, Inc. (NASDAQ:ANIK). Is Anika Therapeutics, Inc. (NASDAQ:ANIK) worth […]
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). To keep it practical, we'll show how Anika Therapeutics, Inc.'s (NASDAQ:ANIK) Read More...
There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.
Anika Therapeutics, Inc. , a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid technology, today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST, at the upcoming ICRS Focus Meeting in Milan, Italy at the Humanitas Research University.
Abeona Therapeutics (ABEO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Anika Therapeutics, Inc. (ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology, today announced that it has resumed global distribution of its solid HA-based treatments, including HYALOFAST, a biodegradable, HA-based cartilage repair scaffold, after a voluntary, non-safety related recall in the second quarter of 2018. Following recent regulatory approvals in Thailand, the United Arab Emirates and Colombia, HYALOFAST has a commercial footprint in approximately 15 countries. “Since May, our quality and operations teams have worked tirelessly to get us back on line to resume shipments before the end of this year, and we’ve delivered on that promise,” said Joseph Darling, President and CEO, Anika Therapeutics.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs in Wednesday's session. Down In The Dumps (Biotech stocks hitting 52-week ...
Anika (ANIK) delivered earnings and revenue surprises of 55.88% and -1.19%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Bedford, Massachusetts-based company said it had net income of 53 cents per share. The medical technology company posted revenue of $26.8 million in the period. Anika shares have decreased 27 percent ...
Anika Therapeutics, Inc. (ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology, announced that, effective immediately, Anika’s Board of Directors has appointed Susan Vogt as an independent director. Ms. Vogt most recently served as Chief Executive Officer and Director of Aushon Biosystems, a venture-backed company with a novel multiplex immunoassay platform.
Anika (ANIK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.